The campaign arrives at a critical juncture for the community, as scientific progress brings a potential first-ever treatment for the LGMD 2I/R9 subtype closer to reality. Kathryn Bryant Knudson, CEO of The Speak Foundation, emphasized that for patients facing progressive decline, the pace of clinical trials remains a matter of urgency. She argued that every biopsy and research contribution from this small patient population must be leveraged to accelerate development, urging Congress to integrate patient perspectives into trial design before, rather than after, study parameters are set.
Advocates Bring Limb-Girdle Muscular Dystrophy Fight to Capitol Hill
Advocates from more than 20 states descended on Washington this week for The Speak Foundation’s LGMD Day on the Hill, conducting over 60 meetings with lawmakers to demand faster regulatory pathways and increased federal investment for the rare, progressive muscle-wasting disease that currently lacks an FDA-approved treatment.
Beyond research funding, the foundation pushed for greater regulatory predictability. Advocates warned that inconsistent requirements often stall development programs, causing investment to evaporate for rare-disease initiatives that already operate on thin margins. To highlight progress in these areas, the organization honored Rep. John Joyce (R-PA) and Rep. Jake Auchincloss (D-MA) with its 2026 Congressional Champion awards. Both lawmakers serve on the House Energy and Commerce Subcommittee on Health, with Joyce having recently championed the bipartisan ORPHAN Cures Act. The foundation maintains that while scientific breakthroughs are within reach, federal policy must now evolve to ensure these innovations successfully transition from the laboratory to the bedside.
1.jpg)
Comments (0)
No comments yet. Be the first!